Resolution of pyoderma gangrenosum using tacolimus (FK-506)

Australian and New Zealand Journal of Medicine

Volumn 26, Issue 2, 1996, Pages 238-239

  Cooley, H M ^b   Castelino, D ^b   McNair, P ^b   Russell, D M ^b   Chohan, V ^b   Kay, T W H ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; DOXYCYCLINE; INTERLEUKIN 2; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG COST; FEMALE; HUMAN; PYODERMA GANGRENOSUM;

EID: 0029886634     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1996.tb00896.x     Document Type: Article

References (5)

1. Schwaegerle SM, Bergfeld WF, Senitzer D et al. Pyoderma Gangrenosum: a review. J Am Acad Dermatol 1988; 18: 559-68.
2. Abu-Elmagd K, Jegasothy BV, Ackerman CD et al. Efficacy of FK 506 in treatment of recalcitrant pyoderma gangrenosum. Transpl Proc 1991; 23: 3328-9.
3. Hooks M. Tacrolimus, a new immunosuppressant - a review of the literature. Ann Pharm 1994; 28: 501-10.
4. European FK 506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK 506) and cyclosporin A in prevention of liver allograft rejection. Lancet 1994; 344: 423-8.
5. Jordan ML, Shapiro R, Vivas CA et al. FK 506 "rescue" for resistant rejection of renal allografts under primary cyclosporin immunosuppression. Transplantation 1994; 57: 860-5.